Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2000
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices for less invasive procedures. Operations are segmented into four geographic regions: United States, Europe, Japan, and Inter-Continental.
Key Financial Metrics
| Metric (in millions) | Q3 2000 | Q3 1999 | 9 Months 2000 | 9 Months 1999 |
|---|---|---|---|---|
| Net Sales | $652 | $691 | $2,026 | $2,125 |
| Gross Profit | $452 | $408 | $1,396 | $1,377 |
| Gross Margin % | 69.3% | 59.0% | 68.9% | 64.8% |
| Operating Income | $132 | $115 | $483 | $506 |
| Net Income | $85 | $55 | $313 | $264 |
| Diluted EPS | $0.21 | $0.13 | $0.76 | $0.64 |
| Cash from Operations (9mo) | $562 | $610 | ||
| Cash & Equivalents (End Period) | ||||
| Total Debt (Short + Long Term) | $860 | $1,278 | $860 | $1,278 |
Note: Debt figures represent the sum of Commercial Paper, Bank Obligations, and Long-term Debt.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6% in Q3 and 5% for the nine-month period compared to 1999. This was driven primarily by a 9% decline in worldwide vascular sales, specifically coronary stents and balloons. U.S. coronary stent revenues dropped from $107 million in Q3 1999 to $68 million in Q3 2000.
- Profitability Improvement: Despite lower sales, Net Income increased 55% in Q3 and 19% for the nine-month period. Gross margins improved significantly (from 59.0% to 69.3% in Q3) due to a $62 million inventory provision recorded in Q3 1999 that did not recur, and better inventory management.
- Special Charges: Q3 2000 included a $23 million pre-tax special charge for a global operations plan (plant optimization and workforce reductions) and a $5 million provision for NIR(R) stent inventory. Q3 1999 included a $62 million inventory provision and $22 million in legal costs.
- Debt Reduction: Total debt obligations decreased significantly as the company repaid approximately $410 million of outstanding debt during the nine months ended September 30, 2000.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Global Operations Plan: Announced in July 2000, this plan aims to increase productivity and innovation. It includes closing three facilities and shifting production. The company estimates pre-tax operating savings of $100 million in 2001, $220 million in 2002, and $250 million annually thereafter.
- Future Costs: The company expects to record an additional $34 million in severance charges and $11 million in transition costs in Q4 2000. Approximately $50 million in expenses are expected in 2001.
- Product Launches: The NIRoyal(TM) Elite Monorail(TM) stent system is expected to launch in all approved sizes in Q1 2001. Gross margins may face pressure in Q4 2000 due to the launch of higher-costing gold-coated stents.
- Effective Tax Rate: The estimated effective tax rate for 2000 was revised down to 30% from 32% due to changes in the geographic mix of business.
Risks and Contingencies
- Supply Chain Risk: The company relies on Medinol Ltd. for NIR(R) coronary stents. Medinol is located in Israel, a region experiencing violence and unrest. The company holds $134 million in NIR(R) inventory and is committed to purchasing an additional $55 million.
- Litigation: The company is involved in extensive patent litigation with competitors including Guidant, Johnson & Johnson (Cordis), Medtronic, and Cook Inc. Potential exposure for litigation-related costs is estimated between $35 million and $49 million.
- Regulatory and DOJ Investigation: The U.S. Department of Justice is investigating the voluntary recall of the NIR ON(R) Ranger(TM) with Sox(TM) coronary stent delivery system. The company settled with the SEC regarding business irregularities in its Japanese subsidiary in August 2000.
- Market Volatility: The coronary stent market is highly competitive with significant market share volatility. Future revenues depend on regulatory approvals for new stent platforms.
Investor Verification Checklist
- Stent Inventory Levels: Verify the status of the $134 million NIR(R) stent inventory and the $55 million purchase commitment from Medinol, given supply chain risks in Israel.
- Restructuring Execution: Monitor the execution of the global operations plan, specifically the closure of facilities and the realization of the projected $100 million in 2001 savings.
- Legal Exposure: Track the outcomes of pending patent lawsuits, particularly those involving the NIR(R) stent and the BX Velocity delivery system, which could impact future revenue streams.
- Margin Sustainability: Assess whether gross margins can be maintained as the company transitions to higher-costing stent products in late 2000 and 2001.
- DOJ Investigation: Review any updates regarding the Department of Justice investigation into the 1998 stent recall.